Overview
ARQ 531 represents a next-generation therapeutic approach in hematologic oncology, developed by ArQule (now Merck & Co.). As a potent, orally bioavailable small molecule, it uniquely inhibits both wild-type Bruton's tyrosine kinase (BTK) and the C481S mutant form that confers resistance to ibrutinib and acalabrutinib. Its mechanism involves non-covalent binding to BTK's ATP pocket, allowing sustained target engagement even in resistant disease settings. Preclinical studies demonstrated ARQ 531's broad kinase inhibition profile, particularly against TEC family kinases beyond BTK. This polypharmacology may contribute to enhanced efficacy in certain lymphoid malignancies. The compound entered Phase 1 clinical trials in 2016, showing promise for relapsed/refractory chronic lymphocytic leukemia and other B-cell neoplasms where first-generation BTK inhibitors fail.
Physical and Chemical Properties
ARQ 531 is a crystalline organic compound with moderate lipophilicity (calculated LogP ~3.5), facilitating cell membrane penetration while maintaining reasonable solubility in pharmaceutical vehicles. The molecule's core structure incorporates a pyrazolopyrimidine scaffold, contributing to its selective kinase binding affinity. Its molecular weight of 542.03 g/mol falls within the typical range for orally administered kinase inhibitors. Stability studies indicate ARQ 531 remains intact under standard laboratory storage conditions when protected from light and humidity. The compound shows pH-dependent solubility, with optimal dissolution in slightly acidic to neutral buffers. Analytical characterization typically employs HPLC with UV detection (λmax ~260 nm) and mass spectrometric confirmation for purity verification in research samples.
Main Applications
ARQ 531's primary clinical application targets B-cell malignancies with BTK pathway dependence, particularly those developing resistance to covalent BTK inhibitors. Ongoing trials focus on chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and diffuse large B-cell lymphoma (DLBCL) populations who have exhausted standard therapies. Its ability to inhibit both wild-type and mutant BTK positions it as a potential salvage therapy. Beyond hematologic cancers, preclinical investigations explore ARQ 531's utility in autoimmune disorders where BTK plays a pathogenic role, such as rheumatoid arthritis. Research-grade material serves tool compound purposes in immunology and signal transduction studies, helping elucidate BTK's broader biological functions beyond oncology applications.
Safety and Storage
As an investigational compound, ARQ 531 requires careful handling per institutional biosafety guidelines for bioactive small molecules. Laboratory-scale quantities should be manipulated in fume hoods with appropriate personal protective equipment (nitrile gloves, lab coat, eye protection). The compound's safety profile in humans continues to be evaluated in clinical trials, with early data suggesting manageable toxicity. For long-term storage, ARQ 531 should be maintained at -20°C in airtight, light-resistant containers with desiccant packs to prevent hydrolysis. Solutions in DMSO are stable for several weeks when stored frozen (-20°C) and protected from repeated freeze-thaw cycles. Waste disposal must comply with local regulations for pharmaceutical research compounds.
B2B Procurement Guide
Research-grade ARQ 531 is available through specialized chemical suppliers catering to pharmaceutical R&D, typically in milligram to gram quantities. Procurement requires documentation of intended research use due to its investigational status. Leading suppliers include MedChemExpress, Selleckchem, and Cayman Chemical, with purity specifications generally ≥98% by HPLC. Bulk quantities for clinical trial manufacturing are exclusively available through Merck & Co.'s authorized channels. Pricing reflects the compound's developmental stage, with research samples commanding premium costs. Academic and corporate buyers should verify supplier certifications and request batch-specific analytical data. Lead times for custom synthesis orders typically range 4-8 weeks. International shipments may require special permits due to controlled substance regulations in some jurisdictions.
Related Manufacturers
- 主营：恶唑烷、赤霉素、溴苯基、联噻吩、果糖嗪、咪唑并、屎米酮、碘吡啶、氟苯基、安美速、s-4-苄基、3-溴吲哚、4-氯吡啶、1-乙酸基、氯苯甲酸、咪唑乙醇、氧代丙腈、贝达喹啉、贝伐单抗、谷氨酰胺、喹啉-21氢、决明内酯、溴喹唑啉、苯基丙基、乙基己基
- 主营：抑制剂、化合物库、药物筛选、天然产物